Clinical trials: Oropharyngeal Cancer
Oropharyngeal Neoplasms
Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
The purpose of this study is to determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias.
- Trial name
- NCT00251381
- Testing
- Cetuximab
- Where
- 18 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Trial Form Support S.L.
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx
The diagnostic and pre-therapeutic assessment of squamous cell carcinomas requires a neck and chest CT scan and a neck and facial MRI, which is the most effective examination, to establish the TNM stage of the tumor.
- Trial name
- DECT-CEco (NCT07343271)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Squamous Cell Carcinoma of the Oropharynx
Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma
Hypoxia imaging has not been studied extensively by combining PET and MRI data. Few studies performed the double imaging and none associated anatomopathology with it .
- Trial name
- HYPONECK (NCT04031534)
- Testing
- F-Miso PET scan coupled with MRI
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Centre Henri Becquerel
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A*0201-positive…
- Conditions
- Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor, Locally Advanced
- Trial name
- NCT07172256
- Testing
- CUE-101, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yale University
Head and Neck Cancer
Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- CAPRA (NCT01333085)
- Testing
- carboplatin, RAD001, paclitaxel
- Where
- 5 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
This phase II clinical trial studies how well soy isoflavones work in preventing head and neck cancer in patients with stage I-IV head and neck cancer undergoing surgery.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT02007200
- Testing
- Laboratory Biomarker Analysis, Soy Isoflavones, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Phase I-II Study on Treatment of Advanced Oropharynx Cancer in Elderly Population by Intensity Modulated Radiotherapy With Treatment Volume Reduction and Combination Chemotherapy
It is currently estimated that above 50% of new cancer cases are diagnosed in the elderly population[1]. With the increased life expectancy in the industrialised countries, the incidence of head and neck cancers has significantly…
- Trial name
- NCT01709006
- Testing
- Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Head and Neck Cancer
Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00011999
- Testing
- cisplatin, paclitaxel, conventional surgery
- Where
- 234 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer, Mucositis
Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer
RATIONALE: Growth factors, such as palifermin, may lessen the severity of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy for head and neck cancer.
- Conditions
- Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
- Trial name
- NCT00360971
- Testing
- palifermin, cisplatin, neck dissection
- Where
- 48 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Radiation Therapy Oncology Group
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma
Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
This phase II trial studies how well nivolumab, carboplatin, and paclitaxel work in treating patients with stage III-IV head and neck squamous cell carcinoma that can be removed by surgery.
- Conditions
- Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT03342911
- Testing
- Paclitaxel, Carboplatin, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous…
- Conditions
- Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
- Trial name
- VERSATILE002 (NCT04260126)
- Testing
- Pembrolizumab (KEYTRUDA®) and PDS0101
- Where
- 23 sites in United States, Ireland and 2 more
- Volunteers
- 95 people
- Sponsor
- PDS Biotechnology Corp.
HPV-Related Squamous Cell Carcinoma
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with…
- Trial name
- NCT06563479
- Testing
- FMISO-PET Scan, Chemoradiation, Assessments
- Where
- 9 sites in United States
- Volunteers
- 291 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mouth Neoplasms, Oropharyngeal Neoplasms
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
This is an imaging protocol only, not a therapeutic study. The primary goal of the proposed study is to examine the utility of a new imaging study, Positron Emission Tomography with F-18 Fluorothymidine (FLT PET), in the early…
- Conditions
- Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT00721799
- Testing
- 18F-Fluorothymidine PET scan
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Squamous Cell Carcinoma of the Oropharynx, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
Oropharyngeal squamous cell carcinoma (OPSCC), commonly known as throat cancer or tonsil cancer, has seen a dramatic rise in incidence over the last twenty years.
- Trial name
- NCT05119036
- Testing
- 44 doses of radiation, 54 doses of radiation
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- Indiana University
Oropharyngeal Cancer
Lymphatic Mapping Of Oropharyngeal Cancer
A multi-centre validation study to evaluate whether a new imaging and surgical protocol would work as well as the current gold standard in identifying sentinel nodes in patients with oropharyngeal cancer.
- Trial name
- LOOC (NCT04498221)
- Testing
- Imaging procedure, Surgical procedure
- Where
- 2 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College, London
Oropharynx Squamous Cell Carcinoma
Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)
The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for…
- Trial name
- MER-HPV (NCT05649865)
- Testing
- Blood sample
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Region Skane
Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma
pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
This phase II trial tests how well pB1-11 and human papillomavirus tumor antigen (TA-HPV) vaccines in combination with pembrolizumab work in treating patients with oropharyngeal cancer that has come back (recurrent) or that has…
- Trial name
- NCT05799144
- Testing
- DNA Vaccine, Human Papillomavirus Tumor Antigen Vaccine, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Michael K. Gibson
Pulmonary Disease, Oropharyngeal Disease
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
This study will examine bacteria and toxins in the mouth, lung and digestive system that may be the cause of various diseases or symptoms. H.
- Conditions
- Pulmonary Disease, Oropharyngeal Disease, Lymphangioleiomyomatosis, Pulmonary Fibrosis
- Trial name
- NCT00366509
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Oropharyngeal Cancer
Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
Cancer of the oropharynx (middle, side and back walls of the throat; back of the tongue; soft palate, and tonsils), or oropharyngeal squamous cell carcinoma (OPSCC), has been on the rise in the United States.
- Trial name
- NCT02147418
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance